|
|
发表于 7-10-2009 05:02 PM
|
显示全部楼层
|
YMZ09.CBT Mini Dow Jones Indus.-$5 Dec 09 9,692.00 4:52am ET Up 38.00 (0.39%) |
|
|
|
|
|
|
|
|
|
|
|
发表于 7-10-2009 05:05 PM
|
显示全部楼层
News
CEL SCI to Report Positive Results in CEL 2000 L.E.A.P.S application for Rheumatoid Arthritis 0 comments
Oct 6, 2009 10:33 PM | about stocks: CVM
Today’s unfortunate reporting of the confusion surrounding the Pablo Romanus M.D. affair has left CEL SCI shareholders wondering how a promising biotech firm could suffer from such disinformation. The SEC seems powerless to stop the internet media from printing unsubstantiated rumors which inevitably get followed by heavy shorting of these small cap companys' stock. It’s a shame because there is a real danger of losing very promising technologies if the SEC does not wake up and start investigating this issue. That’s the bad news.
Now for the good news: CEL SCI is about to present a rather significant and successful milestone in their research pertaining to their collagen type II (bovine) induced arthritis(CIA) induced arthritis murine model. The results will be presented in the poster session at the ACR/ARHP Annual Scientific Meeting on October 18, 2009. In their model, 7 to 8 week old mice were induced to an arthritic Index (AI) of 3.5. The mice were either treated with CEL-2000 L.E.A.P.S. experimental therapeutic vaccine, Enbrel (an FDA approved arthritic treatment), or untreated. The results show that there was a statistically significant, (p < 0.05), reduction in footpad swelling, AI score, tissue indicating manifestations of disease, and levels of 22 cytokines/chemokines. In addition, the CEL-2000 L.E.A.P.S technology appears to have performed better than Enbrel. The final conclusion is that the CEL-2000 vaccine arrested the development of rheumatoid arthritis in the model. This is great news for L.E.A.P.S speculators.
Themes: CEL SCI, LEAPS, rheumatoid arthritis Stocks: CVM |
|
|
|
|
|
|
|
|
|
|
|
发表于 7-10-2009 08:15 PM
|
显示全部楼层
CVM
Pre Market LastDone 1.42 |
|
|
|
|
|
|
|
|
|
|
|
发表于 7-10-2009 08:45 PM
|
显示全部楼层
RPRX
0.890
0.000 (0.00%)
Pre-market: 2.160 +1.270 (142.70%) <<<<<< 春天终于来了....忘了是谁坚守这股 .....恭喜 ! 赚一番了
Oct 7, 8:41AM EDT |
|
|
|
|
|
|
|
|
|
|
|
发表于 7-10-2009 09:31 PM
|
显示全部楼层
RPRX VS CTIC
个人看法，那些真的要飞的股，是不会像CTIC, HEB 放出消息。。某某药物即将被批准。
RPRX 就是一个例子。
CTIC跌破$1了。HEB 也没有影子了。。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 7-10-2009 10:30 PM
|
显示全部楼层
好消息 ！
CEL-SCI Presents Solid Science As Detractors Keep Changing the Subject
Last update: 10/7/2009 9:25:00 AM
LOS ANGELES, Oct 07, 2009 (BUSINESS WIRE) -- BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special editorial report about CEL-SCI Corporation's (CVM) presentation of data about the company's dendritic H1N1 treatment, being developed as a treatment for H1N1 hospitalized patients.
The company has attracted a great deal of interest from the biomedical investment community and while some Wall Street reporters have painted the company as little more than the latest "flu stock" play, the fact remains that both the FDA and the medical research community has taken notice of the promising new technology platform.
As indicated in the new editorial report by bio tech investment writer, Vinny Cassano, the data presented by Dr. Ken S. Rosenthal, Ph.D., Professor, Microbiology, Immunology and Biochemistry, Northeastern Ohio Universities Colleges of Medicine and Pharmacology is the only set of facts sanctioned by the company.
"There appears to be a bad-natured effort to keep negative headlines alive and to draw attention away from the facts and reports that have investors trading the stock at volume levels that haven't been seen by the company for years," writes Cassano.
The complete special report is available now at BioMedReports.Com:
Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. The company is not paid or compensated to report news and developments about publicly traded companies.
For more biomedical sector and investment news go to
SOURCE: BioMedReports.com
BiomedReports.Com M. Davila, Editor, +1 323-472-4480 Fax: +1 888-210-3556 info@biomedreports.com
Copyright Business Wire 2009 |
|
|
|
|
|
|
|
|
|
|
|
发表于 7-10-2009 10:31 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 7-10-2009 10:48 PM
|
显示全部楼层
http://www.investmentu.com/IUEL/ ... in-health-care.html
好消息。。。
Three Small-Cap Firms That Could Cash in on Immunotherapy
But there are also many small-cap health care companies engaged in immunotherapy research, which stand to make piles of money for shareholders if they develop a successful drug. Here are some names to look into…
* Dendreon Corp. (Nasdaq: DNDN): Prostate cancer is the most common cancer among American men and is the second-highest cause of cancer deaths. However, Dendreon’s leading drug candidate for prostate cancer, Provenge, could be approved in 2010.
* Cel-Sci Corp. (AMEX: CVM): The company’s Multikine drug, which treats head and neck cancer has completed Phase II trials and its scientists are currently working on an H1N1 flu drug, too.
* Northwest Biotherapeutics (OTC BB: NWBO): The firm has several drugs in various phases of clinical trials for brain, prostate and lung cancers, including DCVax-Prostate and DCVax-LB for non-small cell lung cancer. It also has DCVax-Direct, which treats ovarian, head and neck cancer. |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 7-10-2009 11:04 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 7-10-2009 11:48 PM
|
显示全部楼层
回复 104# m.i.k.e 的帖子
謝謝。那個人就是我。 Buy @ USD 1.4261 and sell @ USD 2.20. 有4500 unit 在手﹐ 賺了大約USD 3400.... |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 7-10-2009 11:53 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 8-10-2009 01:04 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 8-10-2009 01:09 AM
|
显示全部楼层
1.14
+0.16 (16.33%)
Real-time: 1:07PM EDT |
|
|
|
|
|
|
|
|
|
|
|
发表于 8-10-2009 07:45 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 8-10-2009 07:56 AM
|
显示全部楼层
原帖由 m.i.k.e 于 8-10-2009 07:45 AM 发表 
你是指 CTIC 是吗?
美股真的是大跌大起,波动大,而且充满奇迹.
个人认为,最重要的是运气,其次是拿票的能力,第三是耐力.
其实美股跌时,我们这种小户也不需要惊慌失措,只要有能力拿票和确保公司不 BK,迟早是会 ...
对。。我指的是 CTIC....
其实 预测到它肯定会下。。因为 james bianco 和其它 CTIC staff 纷纷卖掉手头上的股了。（马后炮）。。？
我再 等它的 新低。。。。下破 1块。。。。我可以买更多。。。
就算 去 otc...都有它的价值。。。。。
4月再来看你。。。。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 8-10-2009 08:42 AM
|
显示全部楼层
原帖由 m.i.k.e 于 8-10-2009 07:45 AM 发表 
你是指 CTIC 是吗?
美股真的是大跌大起,波动大,而且充满奇迹.
个人认为,最重要的是运气,其次是拿票的能力,第三是耐力.
其实美股跌时,我们这种小户也不需要惊慌失措,只要有能力拿票和确保公司不 BK,迟早是会 ...
佩服+欣賞 麥麥  （五體投地）
我相信到最後你會是國際區的最大一個贏家。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 8-10-2009 08:43 AM
|
显示全部楼层
原帖由 jochen 于 7-10-2009 11:04 PM 发表
1.59 了。。。恭喜恭喜。。。。
謝謝。 
我的投資/投機的全部還未放，
看這幾天怎樣才決定。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 8-10-2009 08:49 AM
|
显示全部楼层
原帖由 终景 于 7-10-2009 11:48 PM 发表
謝謝。那個人就是我。 Buy @ USD 1.4261 and sell @ USD 2.20. 有4500 unit 在手﹐ 賺了大約USD 3400....
可否說說你買RPRX之后的心情。。
當你買進1.4261 後，股價跌至 0.8多時。。
你那時心裏有什么打算？ |
|
|
|
|
|
|
|
|
|
|
|
发表于 8-10-2009 09:17 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 8-10-2009 09:20 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
2147 
59
